Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.56 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.56 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.56 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27757196 | 1.00 | KMT2A (0.56) | KMT2ACYP1A2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL138281 | 1.00 | KMT2A (0.56) | KMT2ACYP1A2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL1706675 | 1.00 | KMT2A (0.56) | KMT2ACYP1A2SLC1A3SLC1A2SLC1A1 | |
| Hydrochloric Acid SCHEMBL7686303 | 0.98 | KMT2A (0.54) | KMT2ACYP1A2SLC1A3SLC1A2SLC1A1 | |
| Hydrochloric Acid SCHEMBL8687505 | 0.98 | KMT2A (0.54) | KMT2ACYP1A2SLC1A3SLC1A2SLC1A1 | |
| Hydrochloric Acid SCHEMBL8687912 | 0.98 | KMT2A (0.54) | KMT2ACYP1A2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL7933798 | 0.93 | KMT2A (0.50) | KMT2ACYP1A2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL7924569 | 0.91 | KMT2A (0.49) | KMT2ACYP1A2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL7929531 | 0.91 | KMT2A (0.49) | KMT2ACYP1A2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL3260466 | 0.89 | GAA (0.57) | CYP1A2CYP2C9CYP2C19TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 203 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113233972-B | Synthesis method of (R) -2-benzyloxy propionic acid and intermediate thereof | 南京红杉生物科技有限公司 | 2022-09-02 | — | — | CN | claimed |
| CN-113233972-A | Synthesis method of (R) -2-benzyloxy propionic acid and intermediate thereof | 南京红杉生物科技有限公司 | 2021-08-10 | — | — | CN | claimed |
| WO-2026107328-A1 | AGONISTS OF PARATHYROID HORMONE 1 AND INCRETIN RECEPTORS | SEPTERNA, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4698542-A1 | 2-AZABICYCLO[2.2.1]HEPTANE KRAS INHIBITORS | Incyte Corporation (US) | 2026-02-25 | — | — | EP | disclosed |
| US-12552783-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-12545685-B2 | Dispiropyrrolidine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-02-10 | — | — | US | disclosed |
| US-20260008758-A1 | LINEAR DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF | INSMED INCORPORATED | 2026-01-08 | — | — | US | disclosed |
| US-20250206732-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. | 2025-06-26 | — | — | US | disclosed |
| US-12240862-B2 | Inhibitors of peptidylarginine deiminases | GILEAD SCIENCES, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| WO-2025026266-A1 | COMPOUND AS LPAR1 ANTAGONIST, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 武汉朗来科技发展有限公司 | 2025-02-06 | — | — | WO | disclosed |
| US-20240390340-A1 | PYRROLIDINE KRAS INHIBITORS | INCYTE CORP (US) | 2024-11-28 | — | — | US | disclosed |
| EP-1089964-B1 | HYDRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2003-10-29 | — | — | EP | disclosed |
| CN-1310707-A | Novel 2,3,3A,4,9, 9A-hexahydro-8-hydroxy-1H-benzo [ F ] indoles, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM PHARMA (DE) | 2001-08-29 | — | — | CN | disclosed |
| US-6239151-B1 | TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES, OSTEOARTHRITIS, RESPIRATORY DISEASES, TUMORS, CACHEXIA, CARDIOVASCULAR DISEASES, FEVER, HAEMORRHAGE AND SEPSIS, HYDRAZINE DERIVATIVES, | HOFFMANN-LA ROCHE INC. | 2001-05-29 | — | — | US | disclosed |
| EP-1089964-A1 | HYDRAZINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2001-04-11 | — | — | EP | disclosed |
| WO-2000000465-A1 | HYDRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-01-06 | — | — | WO | disclosed |
| US-5731318-A | NEUROLOGICAL DISORDERS | BOEHRINGER INGELHEIM KG (DE) | 1998-03-24 | — | — | US | disclosed |
| US-5607941-A | BENZOMORPHAN DERIVATIVES | BOEHRINGER INGELHEIM KG (DE) | 1997-03-04 | — | — | US | disclosed |
| EP-0521422-B1 | Benzomorphanes and their use as pharmaceuticals | BOEHRINGER INGELHEIM KG (DE) | 1996-05-08 | — | — | EP | disclosed |
| EP-0521422-A1 | Benzomorphanes and their use as pharmaceuticals | BOEHRINGER INGELHEIM KG (DE) | 1993-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545685-B2 | Dispiropyrrolidine derivatives | TP53, MDM2, TP53BP1 | KMT2A 4322/4885CYP1A2 4131/4885SLC1A3 4394/4885 |
| US-20240390340-A1 | PYRROLIDINE KRAS INHIBITORS | KRAS, NRAS, HRAS | KMT2A 3044/4885CYP1A2 4250/4885SLC1A3 4397/4885 |
| US-20250206732-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | KRAS, MDM2, VHL | KMT2A 1675/4885CYP1A2 4428/4885SLC1A3 3968/4885 |
| US-20260008758-A1 | LINEAR DIPEPTIDYL PEPTIDASE 1 INHIBITORS AND USES THEREOF | DPP3, DPP7, DPP9 | KMT2A 4083/4885CYP1A2 1348/4885SLC1A3 704/4885 |
| US-12552783-B2 | Modulators of proteolysis and associated methods of use | CRBN, ADRM1, MDM2 | KMT2A 1095/4885CYP1A2 4695/4885SLC1A3 3837/4885 |
| US-12240862-B2 | Inhibitors of peptidylarginine deiminases | PADI4, PADI2, PADI1 | KMT2A 1652/4885CYP1A2 3908/4885SLC1A3 1612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.